MedTrace Logo

Desensitization Protocol for Highly Sensitized Patients on the Waiting List for Kidney Transplant

NCT01502267 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2012-01-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether high dose IVIG and B cell depleting agents can be used effectively in highly sensitized wait-listed patients.

Conditions

Interventions

DRUG

High dose IVIG and B cell depleting agents

1. IVIG(2g/kg two times on day 1, 30) 2. Rituximab(375mg/m2 on day 3) 3. Bortezomib(1.3mg/m2 four times on day 31, 34, 38, 41)

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Curie Ahn, MD · Seoul National University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2014-01-31
Completion
2016-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01502267 on ClinicalTrials.gov